Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-butyl-1-hydroxyguanidine is a small molecule belonging to the class of n-hydroxyguanidines, characterized by a guanidine group with an attached butyl and hydroxy substituent. It acts as an experimental inhibitor of nitric oxide synthase 1 (NOS1), also known as neuronal nitric oxide synthase. By inhibiting NOS1, it potentially modulates the production of nitric oxide, which plays roles in neurotransmission and vascular regulation. The compound has not been approved for any therapeutic use and remains at the experimental stage[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-butyl-1-hydroxyguanidine.